Br J Cancer: Systematic therapeutic response and gene expression of plasma cell-like urethroid cancer

Pulp cell-like urethroid skin cancer (PUC) is a rare histological subshapon of urethratic tract skin cancer (UC).
has an diffuse growth pattern and is more prone to local development of the disease when diagnosed than traditional UC.
previous studies have shown that in 80 percent of PUC cases, there is a short-cut mutation in the CDH1 gene that encodes E-calcium adhesion proteins.
high methylation in cdH1 initiation regions has also been detected in other PUC cases.
preoperative cisplatin-based chemotherapy strategy can improve the pathological response and cancer-specific survival rate of patients and is an integral part of modern UC therapy.
presence of histological subsypes does not impair the efficacy of preoperative chemotherapy in UC patients with scaly or adenopathic differentiation.
, however, little is known about the practicality of preoperative chemotherapy in PUC patients.
study aims to explore the efficacy of non-metastasis PUC preoperative platinum chemotherapy and the efficacy of late-stage PUC immuno checkpoint inhibitors (ICIs).
data on non-metastasis PUC and late PUC cases treated with ICI were collected in the previous study population and in the main clinical analysis subgroups.
the results with an unsealed queue of published urethra skin cancer patients.
researchers collected information on 81 non-metastasis PUC patients.
patients with limited diseases receiving new complementary chemotherapy, the rates of pathological complete remission and reduction were 12% and 21%, respectively.
of pathological stages in patients was not associated with significant improvement in clinical outcomes.
relapse and overall survival rates in patients with plasma cell-like urethroid cancer were reduced, the researchers found that up to 18 percent of localized disease cases and 28 percent of local late-stage cases during surgery had non-excisible diseases.
of patients with advanced PUC (N s 21) treated with ICI had a progression-free survival and a total survival of 4.5 and 10.5 months, respectively, with a remission rate of 38%.
researchers observed mutations in genes associated with FGFR3 and DNA damage reactions in 3% and 15% of cases, respectively.
, the above results show that PUC is associated with a high burden of disease and poor chemical sensitivity.
awareness of the disease subsype will be conducive to the development of new treatment strategies.